<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Neuromuscular junction disorders in newborns and infants</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Neuromuscular junction disorders in newborns and infants</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Neuromuscular junction disorders in newborns and infants</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Olaf A Bodamer, MD, PhD, FAAP, FACMG</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marc C Patterson, MD, FRACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard Martin, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard P Goddeau, Jr, DO, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 10, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Weakness and hypotonia in newborns can be caused by several conditions, including neuromuscular disorders of the neuromuscular junction. These rare conditions include transient acquired neonatal myasthenia gravis, congenital myasthenia, elevated levels of magnesium or aminoglycosides, and infantile botulism. They are characterized by abnormal neuromuscular transmission leading to muscle fatigability and weakness. Most of these disorders are transient, but congenital forms are permanent.</p><p>Identifying potential neuromuscular causes of hypotonia and weakness (<a class="graphic graphic_table graphicRef66572" href="/d/graphic/66572.html" rel="external">table 1</a>) begins with a thorough clinical assessment. The initial assessment of infants with hypotonia and/or weakness is reviewed separately. (See  <a class="medical medical_review" href="/d/html/6148.html" rel="external">"Approach to the infant with hypotonia and weakness"</a>.)</p><p>Peripheral nerve and muscle disorders that may cause weakness in newborns and infants are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/6151.html" rel="external">"Overview of peripheral nerve and muscle disorders causing hypotonia in the newborn"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">NEONATAL MYASTHENIA GRAVIS</span><span class="headingEndMark"> — </span>Transient neonatal myasthenia gravis (MG) occurs in 10 to 20 percent of infants born to mothers with MG [<a href="#rid1">1</a>]. Most mothers of affected infants have active clinical disease, although some may have little or no evidence of myasthenia or may be in remission [<a href="#rid2">2,3</a>].</p><p>MG is an autoimmune disorder caused by antibodies that usually are directed against the acetylcholine receptor (AChR), resulting in postsynaptic inhibition of neuromuscular transmission [<a href="#rid4">4,5</a>]. (See  <a class="medical medical_review" href="/d/html/5153.html" rel="external">"Pathogenesis of myasthenia gravis"</a>.)</p><p>Maternal AChR antibodies transferred to the fetus are responsible for transient neonatal MG [<a href="#rid1">1</a>]. Higher ratios of antibodies directed against the fetal versus the adult type of AChR in mothers with MG are correlated with an increased likelihood of transmitting the disorder [<a href="#rid6">6</a>].</p><p>Rarely, there are persistent myopathic sequelae related to the fetal acetylcholine receptor inactivation syndrome (FARIS) that may be more common than previously recognized [<a href="#rid7">7</a>]. Although the precise pathophysiologic mechanism is not established, this condition is probably related to elevated levels of maternal AChR antibodies directed against the fetal subunit of the AChR receptor, causing abnormal endplate development of the embryonic neuromuscular junction in a subset of infants [<a href="#rid7">7-9</a>]. The facial and bulbar musculature may be particularly susceptible to permanent injury caused by this process.</p><p>Among mothers with a child affected by transient neonatal MG, the risk of recurrence with subsequent pregnancies is approximately 75 percent [<a href="#rid1">1,4,10</a>]. Women with known or suspected MG should receive appropriate counseling regarding the risk and management of transient neonatal MG in future children [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Clinical features</span><span class="headingEndMark"> — </span>Neonatal MG typically presents within a few hours of birth. Signs are nearly always apparent by the third day of age [<a href="#rid1">1,10,12</a>]. More severely affected infants have a history of polyhydramnios and may have arthrogryposis multiplex (multiple joint contractures) at birth [<a href="#rid13">13</a>].</p><p>Newborns with myasthenia have generalized weakness and hypotonia [<a href="#rid4">4</a>]. However, deep tendon reflexes are always present. Facial diplegia often occurs; ptosis and ophthalmoplegia occur less often. Bulbar weakness is frequent, leading to poor sucking and swallowing and a weak cry [<a href="#rid12">12</a>]. Pooling of secretions and respiratory muscle weakness may contribute to respiratory failure and the need for assisted ventilation.</p><p>With prompt diagnosis and appropriate management, most newborns recover within a few weeks (see <a class="local">'Prognosis'</a> below). Treatment is more difficult and recovery is slower in more severely affected patients and when the diagnosis is delayed.</p><p>In the rare FARIS, there are persistent manifestations characterized by facial and bulbar myopathy or arthrogryposis multiplex congenita, sometimes accompanied by hearing loss or pyloric stenosis [<a href="#rid7">7,9</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of neonatal MG should be suspected in the infant of a mother with myasthenia. If the mother does not have known disease, the diagnostic test is the response of the infant to administration of an acetylcholinesterase inhibitor. The agent used most commonly is <a class="drug drug_pediatric" data-topicid="12640" href="/d/drug information/12640.html" rel="external">neostigmine</a> methylsulfate (0.15 mg/kg intramuscularly or subcutaneously).</p><p>This test should be performed only in a setting where resuscitation can readily be performed. When the test is diagnostic, <a class="drug drug_pediatric" data-topicid="12640" href="/d/drug information/12640.html" rel="external">neostigmine</a> results in clinical improvement that begins in approximately 15 minutes and continues for one to three hours. Success should be determined by a measurable response (eg, an improvement in ventilation or time to drink an amount of fluid) of &gt;15 percent. <a class="drug drug_pediatric" data-topicid="12875" href="/d/drug information/12875.html" rel="external">Atropine</a> may be needed to control muscarinic side effects, such as diarrhea and increased tracheal secretions.</p><p>Some experts prefer the acetylcholinesterase inhibitor <a class="drug drug_pediatric" data-topicid="13266" href="/d/drug information/13266.html" rel="external">edrophonium</a> (0.15 mg/kg intramuscularly or subcutaneously, or intravenously in fractional amounts delivered over several minutes after a test dose of 0.03 mg/kg), but it is no longer available in the United States, Canada, the United Kingdom, the European Union, or many other countries. This agent acts more rapidly than <a class="drug drug_pediatric" data-topicid="12640" href="/d/drug information/12640.html" rel="external">neostigmine</a>, and muscarinic side effects are less intense. However, respiratory arrest has been reported [<a href="#rid1">1</a>].</p><p>Complications of prematurity or hypoxic-ischemic encephalopathy may occasionally interfere with an infant's response to administration of an acetylcholinesterase inhibitor. In these cases, repetitive nerve stimulation can be used to confirm the diagnosis [<a href="#rid14">14</a>]. This test compares the amplitude of the fifth evoked compound muscle action potential with the first, before and after administration of an acetylcholinesterase inhibiting agent. A positive response is reduction of the fifth action potential by 10 percent or more and reversal of this decrement by the acetylcholinesterase inhibitor [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Management</span><span class="headingEndMark"> — </span>Management of neonatal myasthenia is supportive. Small frequent feedings are provided by nasogastric or orogastric tube, and assisted ventilation is provided when indicated. In addition, <a class="drug drug_pediatric" data-topicid="12640" href="/d/drug information/12640.html" rel="external">neostigmine</a> methylsulfate (0.05 to 0.1 mg/kg intramuscularly or subcutaneously) is given 30 minutes before each feeding. When feeding and respiratory abnormalities have improved, the drug can be given orally (0.5 to 1.0 mg/kg orally approximately 45 minutes prior to feeding). Excessive doses may result in increased secretions, diarrhea, weakness, and muscle fasciculations.</p><p>With continued clinical improvement, the <a class="drug drug_pediatric" data-topicid="12640" href="/d/drug information/12640.html" rel="external">neostigmine</a> dose can be lowered gradually. In addition, the course of the disease can be monitored by repeat nerve stimulation testing and measurement of acetylcholine receptor antibodies.</p><p>In one case of a child (age 5 years) with severe facial muscle weakness due to suspected FARIS, prior treatment with <a class="drug drug_pediatric" data-topicid="12752" href="/d/drug information/12752.html" rel="external">pyridostigmine</a> was not beneficial, but there was significant symptom improvement with <a class="drug drug_pediatric" data-topicid="13290" href="/d/drug information/13290.html" rel="external">albuterol</a> [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Prognosis</span><span class="headingEndMark"> — </span>With prompt diagnosis and appropriate management, most newborns recover within a few weeks; 90 percent of patients recover fully before reaching two months of age [<a href="#rid1">1</a>]. Tube feeding and assisted ventilation rarely are required for longer than one to two weeks. The average duration of pharmacologic treatment is four weeks.</p><p>Although data are limited to a few cases, FARIS has been associated with a broad spectrum of severity, ranging from profound arthrogryposis, respiratory weakness, and early death to mild but permanent weakness of the facial and bulbar muscles [<a href="#rid7">7,9</a>].</p><p class="headingAnchor" id="H7"><span class="h1">CONGENITAL MYASTHENIC SYNDROMES</span><span class="headingEndMark"> — </span>The congenital myasthenic syndromes (CMS) are uncommon causes of neuromuscular junction failure in newborns and children (<a class="graphic graphic_table graphicRef52202" href="/d/graphic/52202.html" rel="external">table 2</a>). These heterogeneous disorders are caused by genetic defects in presynaptic, synaptic basal lamina, and postsynaptic components of the neuromuscular junction [<a href="#rid16">16-20</a>]. There is no involvement of the immune system [<a href="#rid21">21</a>].</p><p>The more common types of CMS (<a class="graphic graphic_table graphicRef52202" href="/d/graphic/52202.html" rel="external">table 2</a>) include the following [<a href="#rid17">17,19,22</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Primary acetylcholine receptor (AChR) deficiency, the most frequent type, caused by recessive pathologic variants in any of the AChR subunit genes (<em>CHRNA</em>, <em>CHRNB</em>, <em>CHRND</em>, or <em>CHRNE</em>); most occur in the epsilon subunit (<em>CHRNE</em>)</p><p class="bulletIndent1"><span class="glyph">●</span><em>RAPSN</em> genetic variants, causing impaired clustering of AChR</p><p class="bulletIndent1"><span class="glyph">●</span><em>COLQ</em> genetic variants, leading to endplate acetylcholinesterase deficiency</p><p class="bulletIndent1"><span class="glyph">●</span><em>DOK7</em> genetic variants, resulting in aberrant synaptic maturation and maintenance</p><p class="bulletIndent1"><span class="glyph">●</span><em>CHAT</em> genetic variants, causing presynaptic defects in acetyltransferase</p><p class="bulletIndent1"><span class="glyph">●</span>Fast channel syndrome with abbreviated AChR channel opening, caused by variants in the AChR subunit genes (<em>CHRNA</em>, <em>CHRNB</em>, <em>CHRND</em>, or <em>CHRNE</em>)</p><p class="bulletIndent1"><span class="glyph">●</span>Slow channel syndrome with prolonged AChR channel opening, also caused by variants in the AChR subunit genes (<em>CHRNA</em>, <em>CHRNB</em>, <em>CHRND</em>, or <em>CHRNE</em>)</p><p></p><p class="headingAnchor" id="H8"><span class="h2">Clinical features</span><span class="headingEndMark"> — </span>All forms of CMS are characterized by fatigable weakness, but some forms have distinct phenotypes (<a class="graphic graphic_table graphicRef103283" href="/d/graphic/103283.html" rel="external">table 3</a>). Newborns with CMS frequently have ptosis, in contrast to patients with transient neonatal myasthenia gravis. In addition, several subtypes of CMS (eg, AChR deficiency, acetylcholinesterase deficiency, and fast channel syndrome) typically demonstrate ophthalmoplegia [<a href="#rid21">21</a>]. Bulbar and respiratory muscle weakness are common features in these subtypes. Affected infants may have fluctuating generalized hypotonia and weakness and life-threatening episodes of apnea [<a href="#rid23">23</a>]. Arthrogryposis may be present at birth [<a href="#rid23">23,24</a>].</p><p>CMS has been associated with sudden death in infancy in severe cases [<a href="#rid25">25,26</a>]. For most patients, CMS improves with age, but spontaneous exacerbations may occur. Exacerbations may also be triggered by increased or intense activity, febrile illness, or stress. Exacerbations of CMS symptoms during pregnancy may be common but are typically transient [<a href="#rid27">27</a>].</p><p>Some types of CMS can present later in infancy or childhood.</p><p class="bulletIndent1"><span class="glyph">●</span>The Dok-7 myasthenia syndrome, a congenital myasthenia related to recessive pathologic variants of the <em>DOK7</em> gene, typically becomes symptomatic around age 2 or 3 years, and later onset in adolescence or adulthood has also been reported [<a href="#rid28">28,29</a>]. Limb-girdle distribution weakness is typical; eye movements are usually spared [<a href="#rid21">21</a>]. One study of six patients with <em>DOK7</em> variants found marked phenotypic variability, although all shared the limb-girdle pattern of weakness [<a href="#rid30">30</a>]. In the two most severely affected patients, the onset of weakness and respiratory failure occurred at birth.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Manifestations of <em>RAPSN</em> congenital myasthenia range from severe neonatal hypotonia and arthrogryposis to mild limb muscle weakness [<a href="#rid31">31,32</a>]. Ophthalmoplegia is rare [<a href="#rid21">21</a>]. Early onset is most common but late onset has been described [<a href="#rid32">32,33</a>]. Most patients respond to acetylcholinesterase inhibitors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>DPAGT1</em> gene variants lead to a CMS with prominent limb-girdle weakness and minimal bulbar symptoms, with sparing of eye movements [<a href="#rid21">21,34</a>]. The median age of onset is 2 years (range 0.5 to 7 years). Tubular aggregates are a characteristic feature on muscle biopsy.</p><p></p><p class="headingAnchor" id="H9"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of CMS (<a class="graphic graphic_table graphicRef103283" href="/d/graphic/103283.html" rel="external">table 3</a>) should be suspected in the setting of fatigable weakness affecting mainly the ocular and bulbar muscles, onset at birth to early childhood, and a positive family history [<a href="#rid17">17</a>]. Nonetheless, some types of CMS present later in life, and some present with a limb-girdle distribution of weakness with little or no involvement of the cranial muscles [<a href="#rid17">17,20,21,35,36</a>].</p><p>A diagnostic response to acetylcholinesterase inhibitors may be useful if it is positive. However, some disorders, such as <em>DOK7</em>, slow channel syndrome, and <em>COLQ</em>, may be refractory to these agents or worsened by administration [<a href="#rid21">21</a>]. A decremental response to repetitive nerve stimulation at low frequency (2 Hz) supports the diagnosis, though infants with choline acetyltransferase CMS due to <em>CHAT</em> genetic variants require prolonged stimulation at a higher frequency (10 Hz) to induce a response.</p><p>Targeted genetic testing can be diagnostic when phenotypic characteristics suggest specific genetic variants that cause CMS (<a class="graphic graphic_table graphicRef103283" href="/d/graphic/103283.html" rel="external">table 3</a>) [<a href="#rid17">17</a>]. Next-generation whole-exome sequencing can identify causative genetic variants when targeted genetic testing is not feasible or is nondiagnostic. A definitive genetic diagnosis is useful for guiding treatment, prognosis, and genetic counseling [<a href="#rid17">17,21</a>].</p><p class="headingAnchor" id="H10"><span class="h2">Management</span><span class="headingEndMark"> — </span>The treatment of CMS depends upon the specific disorder (<a class="graphic graphic_algorithm graphicRef105466" href="/d/graphic/105466.html" rel="external">algorithm 1</a>) [<a href="#rid17">17</a>]. A trial of acetylcholinesterase inhibitor treatment (eg, <a class="drug drug_pediatric" data-topicid="12752" href="/d/drug information/12752.html" rel="external">pyridostigmine</a>) is warranted for some but not all types of CMS; certain disorders (eg, <em>DOK7</em>, slow channel syndrome, and <em>COLQ</em> CMS) have a risk of worsening with pyridostigmine and 3,4-diaminopyridine (3,4-DAP) [<a href="#rid21">21</a>].</p><p>For subtypes of CMS that respond to <a class="drug drug_pediatric" data-topicid="12752" href="/d/drug information/12752.html" rel="external">pyridostigmine</a> (eg, primary AChR deficiency, <em>RAPSN</em>, fast channel syndrome, <em>CHAT</em>, glycosylation pathway defects), adjunctive treatment with 3,4-DAP can be beneficial [<a href="#rid16">16,17</a>]. Limited data suggest that <a class="drug drug_pediatric" data-topicid="13290" href="/d/drug information/13290.html" rel="external">albuterol</a> (salbutamol) or <a class="drug drug_pediatric" data-topicid="15973" href="/d/drug information/15973.html" rel="external">ephedrine</a> improves muscle strength and mobility in patients with acetylcholine receptor deficiency caused by <em>CHRNE</em> variants [<a href="#rid37">37</a>].</p><p><a class="drug drug_pediatric" data-topicid="13290" href="/d/drug information/13290.html" rel="external">Albuterol</a> (salbutamol) or <a class="drug drug_pediatric" data-topicid="15973" href="/d/drug information/15973.html" rel="external">ephedrine</a> can be used to treat CMS caused by <em>DOK7</em> and <em>COLQ</em> genetic variants [<a href="#rid16">16,17,20,38</a>]. <a class="drug drug_pediatric" data-topicid="13315" href="/d/drug information/13315.html" rel="external">Fluoxetine</a>, <a class="drug drug_pediatric" data-topicid="12755" href="/d/drug information/12755.html" rel="external">quinidine</a>, or <a class="drug drug_pediatric" data-topicid="12756" href="/d/drug information/12756.html" rel="external">quinine</a> may be used to treat slow channel syndrome [<a href="#rid17">17,39-41</a>].</p><p>Respiratory care is an important aspect of management, since hypoventilation can occur in all subtypes of CMS [<a href="#rid21">21</a>]. Some patients may benefit from noninvasive ventilation at home.</p><p class="headingAnchor" id="H11"><span class="h1">ELEVATED MAGNESIUM OR AMINOGLYCOSIDE LEVELS</span><span class="headingEndMark"> — </span>Excessive concentrations of magnesium or aminoglycosides may inhibit neuromuscular transmission in newborns.</p><p class="headingAnchor" id="H12"><span class="h2">Hypermagnesemia</span><span class="headingEndMark"> — </span>Hypermagnesemia blocks calcium release, resulting in a presynaptic failure of acetylcholine release [<a href="#rid42">42</a>]. Neonatal hypermagnesemia usually results from maternal administration of <a class="drug drug_pediatric" data-topicid="12982" href="/d/drug information/12982.html" rel="external">magnesium sulfate</a>.</p><p>Affected infants are depressed and have generalized hypotonia. Treatment generally consists of supportive care and monitoring. In severe cases, respiratory depression with apnea may occur. Hypermagnesemia also may result in decreased gastrointestinal motility and meconium plug syndrome.</p><p class="headingAnchor" id="H13"><span class="h2">Aminoglycoside toxicity</span><span class="headingEndMark"> — </span>Excess aminoglycoside levels, especially in combination with neuromuscular blockers, may lead to prolonged weakness caused by a presynaptic block. Bladder, bowel, and pupillary functions may be depressed [<a href="#rid43">43</a>]. Hypocalcemia accentuates the neurotoxic effects of aminoglycosides and hypermagnesemia.</p><p class="headingAnchor" id="H14"><span class="h1">INFANT BOTULISM</span><span class="headingEndMark"> — </span>Infant botulism results from intestinal colonization by <em>Clostridium botulinum</em>, which produces a neurotoxin that blocks presynaptic cholinergic transmission, affecting skeletal and smooth muscle and autonomic function [<a href="#rid44">44</a>]. (See  <a class="medical medical_review" href="/d/html/5509.html" rel="external">"Botulism"</a>.)</p><p class="headingAnchor" id="H15"><span class="h2">Epidemiology</span><span class="headingEndMark"> — </span>Infant botulism affects infants between one week and 12 months of age, but most cases occur between two and eight months of age; the median age of onset is three to four months [<a href="#rid45">45,46</a>].</p><p><em>Clostridium</em> species that cause infant botulism include types A, B, E, and F [<a href="#rid47">47-50</a>]. Typing is based upon the antigenic specificities of the toxin produced. The vast majority of cases are due to infection with types A or B [<a href="#rid47">47,51</a>]. Type A is more prevalent in the western United States, and type B is more prevalent in the eastern United States.</p><p>While infant botulism occurs worldwide, the disease occurs more commonly in areas where environmental conditions favor persistence of spores in the soil, including Pennsylvania, Utah, and California in North America [<a href="#rid46">46,52-54</a>]. Most cases in the United States are thought to result from ingestion of environmental dust containing <em>C. botulinum</em> spores, and residence near activities that disturb the soil such as construction or agricultural cultivation may enhance exposure. Foodborne cases can result from ingestion of wild honey or home canned foods contaminated with <em>C. botulinum</em> spores [<a href="#rid55">55</a>].</p><p>Young age and the absence of competitive bowel flora are factors that predispose to vulnerability [<a href="#rid56">56</a>]. Colostrum in breast milk offers some protection, but breastfed infants may become susceptible during the transition to formula or solid foods.</p><p class="headingAnchor" id="H16"><span class="h2">Clinical features</span><span class="headingEndMark"> — </span>The clinical features result from progressive neuromuscular blockade and range from mild to severe. Muscles innervated by the cranial nerves are affected first, followed by those of the trunk, extremities, and diaphragm [<a href="#rid57">57</a>].</p><p>Infants typically present with constipation and poor feeding. This presentation is followed by progressive hypotonia and weakness. Loss of deep tendon reflexes appears to occur more commonly in type B infection [<a href="#rid46">46</a>]. Cranial nerve dysfunction is manifested by decreased gag and suck, diminished range of eye movement, pupillary paralysis, and ptosis. Autonomic signs include decreased tearing and salivation, fluctuating heart rate and blood pressure, and flushed skin.</p><p>Infant botulism may present with or progress to life-threatening respiratory failure, and serious complications may develop during the course. In a clinical trial, most infants required intensive care and about half required mechanical ventilation [<a href="#rid58">58</a>]. In atypical cases, infants may present with catastrophic collapse or rapid deterioration following brief periods of poor feeding but without the typical initial complaints of constipation, ptosis, or facial weakness [<a href="#rid59">59</a>].</p><p>Prior to the advent of human-derived <a class="drug drug_pediatric" data-topicid="13285" href="/d/drug information/13285.html" rel="external">botulism immune globulin</a> (BIG-IV) treatment, the duration of illness was usually one to two months, and occasional infants might relapse [<a href="#rid60">60</a>]. Untreated type A infant botulism was longer in duration and more severe than type B illness [<a href="#rid58">58</a>].</p><p class="headingAnchor" id="H17"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of infant botulism should be suspected in any infant with acute onset of weak suck, ptosis, inactivity, and constipation. However, infant botulism is a rare disorder, and the diagnosis is often missed [<a href="#rid47">47</a>]. As an example, the diagnosis was suspected on admission in only half of the infants enrolled in a randomized trial who had laboratory-confirmed infant botulism [<a href="#rid58">58</a>].</p><p>Serum samples for botulinum toxin are often negative in cases of infant botulism. The diagnosis is supported by the isolation of <em>C. botulinum</em> spores from the stool and is confirmed by the identification of botulinum toxin in stool samples [<a href="#rid46">46</a>]. Fecal excretion may be identified for up to several weeks after symptom onset. However, detection varies by botulism subtype and assay [<a href="#rid61">61</a>]. In addition, stool sample collection can be difficult because constipation is a nearly constant feature of infant botulism. Further, stool sample assays do not yield timely results. Anaerobic cultures often take up to six days for growth and identification of the organism, and initial detection of toxin requires one to four days [<a href="#rid62">62</a>].</p><p>The delays with these confirmatory tests are important since, as described in the next section, therapy should be administered as early as possible [<a href="#rid63">63</a>]. Thus, a presumptive diagnosis should be made based upon the clinical presentation and electrophysiologic findings while the confirmatory stool studies are pending. Electromyography (EMG) findings consistent with infant botulism are not pathognomonic and may not be present early in the course of the disease [<a href="#rid64">64</a>]. Nevertheless, certain EMG findings support the diagnosis of botulism when coupled with the appropriate clinical presentation:</p><p class="bulletIndent1"><span class="glyph">●</span>Repetitive nerve stimulation at rates of 20 to 50 Hz with an abnormal incremental response. An incremental response to 50 Hz stimulation is seen in 92 percent of infants with botulism poisoning, compared with 20 percent of normal infants [<a href="#rid65">65-67</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>EMG showing short-duration, low-amplitude motor unit potentials [<a href="#rid65">65</a>].</p><p></p><p>The differential diagnosis for infant botulism includes brainstem encephalitis, cerebral infarction, dehydration, drug ingestion, Guillain-Barré syndrome, Lambert-Eaton myasthenic syndrome, metabolic encephalopathy, myasthenia gravis, neuromuscular disorders, and sepsis.</p><p>In clinical practice, spinal muscular atrophy type I and metabolic disorders are the most frequent mimics of infant botulism. This conclusion comes from a chart review of all 681 cases of suspected infant botulism treated with human <a class="drug drug_pediatric" data-topicid="13285" href="/d/drug information/13285.html" rel="external">botulism immune globulin</a> from 1992 through mid-2005 [<a href="#rid68">68</a>]. Thirty-two infants (4.7 percent) did not have laboratory-confirmed infant botulism; the final diagnoses included the following categories:</p><p class="bulletIndent1"><span class="glyph">●</span>Spinal muscular atrophy type 1 (n = 5). (See  <a class="medical medical_review" href="/d/html/6146.html" rel="external">"Spinal muscular atrophy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Metabolic disorders (n = 8), including mitochondrial disorders (n = 4).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other infectious diseases (n = 3).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Miscellaneous (n = 7), including a case of Miller Fisher variant of Guillain-Barré syndrome. (See  <a class="medical medical_review" href="/d/html/6235.html" rel="external">"Guillain-Barré syndrome in children: Epidemiology, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Probable infant botulism (n = 9) in cases where laboratory studies to establish the diagnosis were not requested or were not performed.</p><p></p><p class="headingAnchor" id="H18"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>Any infant with clinical signs, symptoms, or history suspicious for botulism should be hospitalized immediately and meticulously monitored for signs of respiratory failure.</p><p>For suspected infant botulism occurring in any state, the California Department of Health Services, Infant Botulism Treatment and Prevention Program should be contacted (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.infantbotulism.org%2F&amp;token=bJ98wEjwYbR6KcGnbD%2BLoUaUh1rT76sWwqsL6cXM9%2FgDbklP8xb8p7OvePxGoEHa&amp;TOPIC_ID=6153" target="_blank">www.infantbotulism.org/</a> or 1-510-231-7600).</p><p><a class="drug drug_pediatric" data-topicid="13285" href="/d/drug information/13285.html" rel="external">Botulism immune globulin</a> intravenous (BIG-IV or BabyBIG), a human-derived botulinum antitoxin, is safe and effective therapy for infant botulism and should be administered as early as possible [<a href="#rid58">58,63,69</a>]. Treatment should not be delayed while awaiting results of confirmatory tests. </p><p>The benefit of BIG-IV was conclusively demonstrated in a randomized controlled trial of 122 infants with infant botulism (75 caused by type A toxin and 47 by type B toxin) who were randomly assigned to treatment with BIG-IV or placebo [<a href="#rid58">58</a>]. The following significant benefits were noted with BIG-IV compared with placebo:</p><p class="bulletIndent1"><span class="glyph">●</span>A reduced mean duration of hospital stay, which was the primary outcome measure (2.6 versus 5.7 weeks)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A reduced mean duration of intensive care (1.8 versus 5 weeks), mechanical ventilation (1.8 versus 4.4 weeks), and tube or intravenous feeding (3.6 versus 10 weeks)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mean hospital charges were reduced by $89,000 (in 2004 United States dollars)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In preplanned subgroup analyses, BIG-IV treatment was beneficial for both type A and type B infant botulism</p><p></p><p>No serious adverse events were associated with BIG-IV therapy.</p><p>In a subsequent open-label study, 382 infants with infant botulism were treated with BIG-IV within 18 days of hospital admission [<a href="#rid58">58</a>]. For 366 infants treated within seven days of hospital admission, the mean length of hospitalization was 2.2 weeks. Early treatment with BIG-IV was associated with shorter mean length of stay compared with later treatment.</p><p>Management of infant botulism is otherwise supportive and includes close monitoring to detect sudden worsening.</p><p>Antibiotics should <strong>not</strong> be prescribed for infant botulism unless indicated for a concurrent infection [<a href="#rid63">63</a>]; there is theoretical concern that lysis of intraluminal <em>C. botulinum</em> could increase the amount of toxin available for absorption [<a href="#rid70">70</a>]. This recommendation is reasonable even though a single BIG-IV infusion should neutralize all botulinum toxin available for absorption for at least six months [<a href="#rid58">58</a>]. Aminoglycoside antibiotics should be avoided because they can rarely cause neuromuscular blockade and thereby exacerbate the paralytic effects of botulism toxin [<a href="#rid63">63</a>].</p><p>Penicillin or <a class="drug drug_pediatric" data-topicid="12606" href="/d/drug information/12606.html" rel="external">metronidazole</a> should be used to treat patients with wound botulism after antitoxin has been administered [<a href="#rid70">70</a>]. Aminoglycosides should be avoided because they can potentiate the effects of the toxin. (See <a class="local">'Aminoglycoside toxicity'</a> above.)</p><p class="headingAnchor" id="H516476395"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuromuscular disorders in newborns</strong> – Weakness and hypotonia in newborns can be caused by disorders of the neuromuscular junction. These rare conditions include transient acquired neonatal myasthenia gravis, congenital myasthenia, elevated levels of magnesium or aminoglycosides, and infantile botulism (<a class="graphic graphic_table graphicRef66572" href="/d/graphic/66572.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transient neonatal myasthenia gravis</strong> – Transient neonatal myasthenia gravis occurs in 10 to 20 percent of infants born to mothers with myasthenia gravis. Newborns with myasthenia have generalized weakness and hypotonia. Facial diplegia and bulbar weakness often occur; ptosis and ophthalmoplegia occur less frequently. Neonatal myasthenia gravis typically presents within a few hours of birth, but signs are nearly always apparent by the third day of age. (See <a class="local">'Neonatal myasthenia gravis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the mother does not have known disease, the diagnostic test is the response of the infant to administration of an acetylcholinesterase inhibitor. Management is supportive.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ninety percent of patients recover fully before reaching two months of age.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Congenital myasthenic syndromes</strong> – The congenital myasthenic syndromes are uncommon causes of neuromuscular junction failure in newborns caused by genetic defects of the neuromuscular junction (<a class="graphic graphic_table graphicRef52202" href="/d/graphic/52202.html" rel="external">table 2</a>). Newborns with congenital myasthenia frequently have ptosis, in contrast with patients with the transient disorder, and typically demonstrate ophthalmoplegia and bulbar and respiratory muscle weakness. Affected infants may have fluctuating generalized hypotonia and weakness and life-threatening episodes of apnea. (See <a class="local">'Congenital myasthenic syndromes'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A definitive genetic diagnosis is useful for directing treatment, supplying prognosis, and providing genetic counseling. The management of CMS depends upon the specific disorder (<a class="graphic graphic_algorithm graphicRef105466" href="/d/graphic/105466.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Congenital myasthenia often improves with age, but spontaneous exacerbations may occur and sometimes result in sudden death in infancy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Elevated magnesium or aminoglycoside levels</strong> – Excessive concentrations of magnesium or aminoglycosides may inhibit neuromuscular transmission in newborns. (See <a class="local">'Elevated magnesium or aminoglycoside levels'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infant botulism</strong> – Infant botulism affects infants between 1 week and 12 months of age. The clinical features result from progressive neuromuscular blockade and range from mild to severe. Muscles innervated by the cranial nerves are affected first, followed by those of the trunk, extremities, and diaphragm. (See <a class="local">'Infant botulism'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The diagnosis should be suspected in any infant with acute onset of weak suck, ptosis, inactivity, and constipation. Infants with clinical signs, symptoms, or history suspicious for botulism should be hospitalized immediately and monitored for signs of respiratory failure.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13285" href="/d/drug information/13285.html" rel="external">Botulism immune globulin</a> intravenous (BIG-IV or BabyBIG) is safe and effective therapy for infant botulism and should be administered as early as possible. Treatment should not be delayed while awaiting results of confirmatory tests.</p><p></p><p class="headingAnchor" id="H974101588"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Geoffrey Miller, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Papazian O. Transient neonatal myasthenia gravis. J Child Neurol 1992; 7:135.</a></li><li><a class="nounderline abstract_t">Elias SB, Butler I, Appel SH. Neonatal myasthenia gravis in the infant of a myasthenic mother in remission. Ann Neurol 1979; 6:72.</a></li><li><a class="nounderline abstract_t">Verspyck E, Mandelbrot L, Dommergues M, et al. Myasthenia gravis with polyhydramnios in the fetus of an asymptomatic mother. Prenat Diagn 1993; 13:539.</a></li><li><a class="nounderline abstract_t">Morel E, Eymard B, Vernet-der Garabedian B, et al. Neonatal myasthenia gravis: a new clinical and immunologic appraisal on 30 cases. Neurology 1988; 38:138.</a></li><li><a class="nounderline abstract_t">Atassi MZ, Oshima M, Deitiker P. On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope. Crit Rev Immunol 2001; 21:1.</a></li><li><a class="nounderline abstract_t">Gardnerova M, Eymard B, Morel E, et al. The fetal/adult acetylcholine receptor antibody ratio in mothers with myasthenia gravis as a marker for transfer of the disease to the newborn. Neurology 1997; 48:50.</a></li><li><a class="nounderline abstract_t">Hacohen Y, Jacobson LW, Byrne S, et al. Fetal acetylcholine receptor inactivation syndrome: A myopathy due to maternal antibodies. Neurol Neuroimmunol Neuroinflamm 2015; 2:e57.</a></li><li><a class="nounderline abstract_t">Jeannet PY, Marcoz JP, Kuntzer T, Roulet-Perez E. Isolated facial and bulbar paresis: a persistent manifestation of neonatal myasthenia gravis. Neurology 2008; 70:237.</a></li><li><a class="nounderline abstract_t">Oskoui M, Jacobson L, Chung WK, et al. Fetal acetylcholine receptor inactivation syndrome and maternal myasthenia gravis. Neurology 2008; 71:2010.</a></li><li><a class="nounderline abstract_t">Namba T, Brown SB, Grob D. Neonatal myasthenia gravis: report of two cases and review of the literature. Pediatrics 1970; 45:488.</a></li><li><a class="nounderline abstract_t">Gilhus NE, Hong Y. Maternal myasthenia gravis represents a risk for the child through autoantibody transfer, immunosuppressive therapy and genetic influence. Eur J Neurol 2018; 25:1402.</a></li><li><a class="nounderline abstract_t">Kochhar PK, Schumacher RE, Sarkar S. Transient neonatal myasthenia gravis: refining risk estimate for infants born to women with myasthenia gravis. J Perinatol 2021; 41:2279.</a></li><li><a class="nounderline abstract_t">Dinger J, Prager B. Arthrogryposis multiplex in a newborn of a myasthenic mother--case report and literature. Neuromuscul Disord 1993; 3:335.</a></li><li><a class="nounderline abstract_t">Hays RM, Michaud LJ. Neonatal myasthenia gravis: specific advantages of repetitive stimulation over edrophonium testing. Pediatr Neurol 1988; 4:245.</a></li><li><a class="nounderline abstract_t">Allen NM, Hacohen Y, Palace J, et al. Salbutamol-responsive fetal acetylcholine receptor inactivation syndrome. Neurology 2016; 86:692.</a></li><li><a class="nounderline abstract_t">Rodríguez Cruz PM, Palace J, Beeson D. Congenital myasthenic syndromes and the neuromuscular junction. Curr Opin Neurol 2014; 27:566.</a></li><li><a class="nounderline abstract_t">Engel AG, Shen XM, Selcen D, Sine SM. Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment. Lancet Neurol 2015; 14:420.</a></li><li><a class="nounderline abstract_t">Aran A, Segel R, Kaneshige K, et al. Vesicular acetylcholine transporter defect underlies devastating congenital myasthenia syndrome. Neurology 2017; 88:1021.</a></li><li><a class="nounderline abstract_t">Finsterer J. Congenital myasthenic syndromes. Orphanet J Rare Dis 2019; 14:57.</a></li><li><a class="nounderline abstract_t">Tayade K, Salunkhe M, Agarwal A, et al. DOK7 congenital myasthenic syndrome responsive to oral salbutamol. QJM 2022; 115:323.</a></li><li><a class="nounderline abstract_t">Finlayson S, Beeson D, Palace J. Congenital myasthenic syndromes: an update. Pract Neurol 2013; 13:80.</a></li><li><a class="nounderline abstract_t">Öztürk S, Güleç A, Erdoğan M, et al. Congenital Myasthenic Syndromes in Turkey: Clinical and Molecular Characterization of 16 Cases With Three Novel Mutations. Pediatr Neurol 2022; 136:43.</a></li><li><a class="nounderline abstract_t">Zafeiriou DI, Pitt M, de Sousa C. Clinical and neurophysiological characteristics of congenital myasthenic syndromes presenting in early infancy. Brain Dev 2004; 26:47.</a></li><li><a class="nounderline abstract_t">Smit LM, Jennekens FG, Veldman H, Barth PG. Paucity of secondary synaptic clefts in a case of congenital myasthenia with multiple contractures: ultrastructural morphology of a developmental disorder. J Neurol Neurosurg Psychiatry 1984; 47:1091.</a></li><li><a class="nounderline abstract_t">Sieb JP, Kraner S, Steinlein OK. Congenital myasthenic syndromes. Semin Pediatr Neurol 2002; 9:108.</a></li><li><a class="nounderline abstract_t">Byring RF, Pihko H, Tsujino A, et al. Congenital myasthenic syndrome associated with episodic apnea and sudden infant death. Neuromuscul Disord 2002; 12:548.</a></li><li><a class="nounderline abstract_t">O'Connell K, Rooney T, Alabaf S, et al. Pregnancy outcomes in patients with congenital myasthenic syndromes. Muscle Nerve 2022; 66:345.</a></li><li><a class="nounderline abstract_t">Müller JS, Herczegfalvi A, Vilchez JJ, et al. Phenotypical spectrum of DOK7 mutations in congenital myasthenic syndromes. Brain 2007; 130:1497.</a></li><li><a class="nounderline abstract_t">Beeson D, Higuchi O, Palace J, et al. Dok-7 mutations underlie a neuromuscular junction synaptopathy. Science 2006; 313:1975.</a></li><li><a class="nounderline abstract_t">Anderson JA, Ng JJ, Bowe C, et al. Variable phenotypes associated with mutations in DOK7. Muscle Nerve 2008; 37:448.</a></li><li><a class="nounderline abstract_t">Ohno K, Engel AG, Shen XM, et al. Rapsyn mutations in humans cause endplate acetylcholine-receptor deficiency and myasthenic syndrome. Am J Hum Genet 2002; 70:875.</a></li><li><a class="nounderline abstract_t">Burke G, Cossins J, Maxwell S, et al. Rapsyn mutations in hereditary myasthenia: distinct early- and late-onset phenotypes. Neurology 2003; 61:826.</a></li><li><a class="nounderline abstract_t">Milone M, Shen XM, Selcen D, et al. Myasthenic syndrome due to defects in rapsyn: Clinical and molecular findings in 39 patients. Neurology 2009; 73:228.</a></li><li><a class="nounderline abstract_t">Finlayson S, Palace J, Belaya K, et al. Clinical features of congenital myasthenic syndrome due to mutations in DPAGT1. J Neurol Neurosurg Psychiatry 2013; 84:1119.</a></li><li><a class="nounderline abstract_t">Rodríguez Cruz PM, Belaya K, Basiri K, et al. Clinical features of the myasthenic syndrome arising from mutations in GMPPB. J Neurol Neurosurg Psychiatry 2016; 87:802.</a></li><li><a class="nounderline abstract_t">Belaya K, Rodríguez Cruz PM, Liu WW, et al. Mutations in GMPPB cause congenital myasthenic syndrome and bridge myasthenic disorders with dystroglycanopathies. Brain 2015; 138:2493.</a></li><li><a class="nounderline abstract_t">Rodríguez Cruz PM, Palace J, Ramjattan H, et al. Salbutamol and ephedrine in the treatment of severe AChR deficiency syndromes. Neurology 2015; 85:1043.</a></li><li><a class="nounderline abstract_t">Tsao CY. Effective Treatment With Albuterol in DOK7 Congenital Myasthenic Syndrome in Children. Pediatr Neurol 2016; 54:85.</a></li><li><a class="nounderline abstract_t">Zhu H, Grajales-Reyes GE, Alicea-Vázquez V, et al. Fluoxetine is neuroprotective in slow-channel congenital myasthenic syndrome. Exp Neurol 2015; 270:88.</a></li><li><a class="nounderline abstract_t">Peyer AK, Abicht A, Heinimann K, et al. Quinine sulfate as a therapeutic option in a patient with slow channel congenital myasthenic syndrome. Neuromuscul Disord 2013; 23:571.</a></li><li><a class="nounderline abstract_t">Harper CM, Engel AG. Quinidine sulfate therapy for the slow-channel congenital myasthenic syndrome. Ann Neurol 1998; 43:480.</a></li><li><a class="nounderline abstract_t">Lipsitz PJ. The clinical and biochemical effects of excess magnesium in the newborn. Pediatrics 1971; 47:501.</a></li><li><a class="nounderline abstract_t">Wright EA, McQuillen MP. Antibiotic-induced neuromuscular blockade. Ann N Y Acad Sci 1971; 183:358.</a></li><li><a class="nounderline abstract_t">Sobel J. Botulism. Clin Infect Dis 2005; 41:1167.</a></li><li><a class="nounderline abstract_t">Thompson JA, Glasgow LA, Warpinski JR, Olson C. Infant botulism: clinical spectrum and epidemiology. Pediatrics 1980; 66:936.</a></li><li><a class="nounderline abstract_t">Thompson JA, Filloux FM, Van Orman CB, et al. Infant botulism in the age of botulism immune globulin. Neurology 2005; 64:2029.</a></li><li><a class="nounderline abstract_t">Koepke R, Sobel J, Arnon SS. Global occurrence of infant botulism, 1976-2006. Pediatrics 2008; 122:e73.</a></li><li><a class="nounderline abstract_t">Barash JR, Tang TW, Arnon SS. First case of infant botulism caused by Clostridium baratii type F in California. J Clin Microbiol 2005; 43:4280.</a></li><li><a class="nounderline abstract_t">Lúquez C, Dykes JK, Yu PA, et al. First report worldwide of an infant botulism case due to Clostridium botulinum type E. J Clin Microbiol 2010; 48:326.</a></li><li><a class="nounderline abstract_t">Moodley A, Quinlisk P, Garvey A, et al. Notes from the field: infant botulism caused by Clostridium baratii type F - Iowa, 2013. MMWR Morb Mortal Wkly Rep 2015; 64:400.</a></li><li><a class="nounderline abstract_t">Fox CK, Keet CA, Strober JB. Recent advances in infant botulism. Pediatr Neurol 2005; 32:149.</a></li><li><a class="nounderline abstract_t">Long SS, Gajewski JL, Brown LW, Gilligan PH. Clinical, laboratory, and environmental features of infant botulism in Southeastern Pennsylvania. Pediatrics 1985; 75:935.</a></li><li><a class="nounderline abstract_t">Arnon SS, Damus K, Chin J. Infant botulism: epidemiology and relation to sudden infant death syndrome. Epidemiol Rev 1981; 3:45.</a></li><li><a class="nounderline abstract_t">Dabritz HA, Hill KK, Barash JR, et al. Molecular epidemiology of infant botulism in California and elsewhere, 1976-2010. J Infect Dis 2014; 210:1711.</a></li><li><a class="nounderline abstract_t">Chin J, Arnon SS, Midura TF. Food and environmental aspects of infant botulism in California. Rev Infect Dis 1979; 1:693.</a></li><li><a class="nounderline abstract_t">Arnon SS, Damus K, Thompson B, et al. Protective role of human milk against sudden death from infant botulism. J Pediatr 1982; 100:568.</a></li><li><a class="nounderline abstract_t">Long SS. Infant botulism. Pediatr Infect Dis J 2001; 20:707.</a></li><li><a class="nounderline abstract_t">Arnon SS, Schechter R, Maslanka SE, et al. Human botulism immune globulin for the treatment of infant botulism. N Engl J Med 2006; 354:462.</a></li><li><a class="nounderline abstract_t">Mitchell WG, Tseng-Ong L. Catastrophic presentation of infant botulism may obscure or delay diagnosis. Pediatrics 2005; 116:e436.</a></li><li><a class="nounderline abstract_t">Glauser TA, Maguire HC, Sladky JT. Relapse of infant botulism. Ann Neurol 1990; 28:187.</a></li><li><a class="nounderline abstract_t">Dabritz HA, Payne JR, Khouri JM. Duration of Fecal Excretion of Clostridium Botulinum and Botulinum Neurotoxin in Patients Recovering from Infant Botulism. J Pediatr 2023; 258:113396.</a></li><li><a class="nounderline abstract_t">Wigginton JM, Thill P. Infant botulism. A review of the literature. Clin Pediatr (Phila) 1993; 32:669.</a></li><li class="breakAll">American Academy of Pediatrics. Botulism and infant botulism. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.266.</li><li><a class="nounderline abstract_t">Hyslop AE, Droker BS, Jansen LA. Clinical reasoning: an unexpected diagnosis in a 4-month-old infant with lethargy and H1N1 influenza. Neurology 2011; 76:e88.</a></li><li><a class="nounderline abstract_t">Cornblath DR, Sladky JT, Sumner AJ. Clinical electrophysiology of infantile botulism. Muscle Nerve 1983; 6:448.</a></li><li><a class="nounderline abstract_t">CHURCHILL-DAVIDSON HC, WISE RP. Neuromuscular transmission in the newborn infant. Anesthesiology 1963; 24:271.</a></li><li><a class="nounderline abstract_t">Koenigsberger MR, Patten B, Lovelace RE. Studies of neuromuscular function in the newborn. I. A comparison of myoneural function in the full term and the premature infant. Neuropadiatrie 1973; 4:350.</a></li><li><a class="nounderline abstract_t">Francisco AM, Arnon SS. Clinical mimics of infant botulism. Pediatrics 2007; 119:826.</a></li><li><a class="nounderline abstract_t">Chalk CH, Benstead TJ, Keezer M. Medical treatment for botulism. Cochrane Database Syst Rev 2014; :CD008123.</a></li><li class="breakAll">Hodowanec A, Bleck TP. Clostridium botulinum (Botulism). In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 8th ed, Bennett JE, Dolin R, Blaser MJ (Eds), Elsevier Saunders, Philadelphia 2015. p.2763.</li></ol></div><div id="topicVersionRevision">Topic 6153 Version 38.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1573230" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Transient neonatal myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/574370" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Neonatal myasthenia gravis in the infant of a myasthenic mother in remission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8372081" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Myasthenia gravis with polyhydramnios in the fetus of an asymptomatic mother.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3336445" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Neonatal myasthenia gravis: a new clinical and immunologic appraisal on 30 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11642597" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9008493" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The fetal/adult acetylcholine receptor antibody ratio in mothers with myasthenia gravis as a marker for transfer of the disease to the newborn.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25566546" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Fetal acetylcholine receptor inactivation syndrome: A myopathy due to maternal antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18195270" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Isolated facial and bulbar paresis: a persistent manifestation of neonatal myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19064884" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Fetal acetylcholine receptor inactivation syndrome and maternal myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5309787" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Neonatal myasthenia gravis: report of two cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30133097" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Maternal myasthenia gravis represents a risk for the child through autoantibody transfer, immunosuppressive therapy and genetic influence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33597740" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Transient neonatal myasthenia gravis: refining risk estimate for infants born to women with myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8268731" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Arthrogryposis multiplex in a newborn of a myasthenic mother--case report and literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3242526" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Neonatal myasthenia gravis: specific advantages of repetitive stimulation over edrophonium testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26791147" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Salbutamol-responsive fetal acetylcholine receptor inactivation syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25159927" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Congenital myasthenic syndromes and the neuromuscular junction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25792100" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28188302" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Vesicular acetylcholine transporter defect underlies devastating congenital myasthenia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30808424" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Congenital myasthenic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35092298" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : DOK7 congenital myasthenic syndrome responsive to oral salbutamol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23468559" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Congenital myasthenic syndromes: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36099689" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Congenital Myasthenic Syndromes in Turkey: Clinical and Molecular Characterization of 16 Cases With Three Novel Mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14729415" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Clinical and neurophysiological characteristics of congenital myasthenic syndromes presenting in early infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6094728" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Paucity of secondary synaptic clefts in a case of congenital myasthenia with multiple contractures: ultrastructural morphology of a developmental disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12138995" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Congenital myasthenic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12117478" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Congenital myasthenic syndrome associated with episodic apnea and sudden infant death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35661384" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Pregnancy outcomes in patients with congenital myasthenic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17439981" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Phenotypical spectrum of DOK7 mutations in congenital myasthenic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16917026" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Dok-7 mutations underlie a neuromuscular junction synaptopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18161030" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Variable phenotypes associated with mutations in DOK7.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11791205" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Rapsyn mutations in humans cause endplate acetylcholine-receptor deficiency and myasthenic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14504330" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Rapsyn mutations in hereditary myasthenia: distinct early- and late-onset phenotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19620612" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Myasthenic syndrome due to defects in rapsyn: Clinical and molecular findings in 39 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23447650" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Clinical features of congenital myasthenic syndrome due to mutations in DPAGT1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27147698" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Clinical features of the myasthenic syndrome arising from mutations in GMPPB.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26133662" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Mutations in GMPPB cause congenital myasthenic syndrome and bridge myasthenic disorders with dystroglycanopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26296515" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Salbutamol and ephedrine in the treatment of severe AChR deficiency syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26552645" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Effective Treatment With Albuterol in DOK7 Congenital Myasthenic Syndrome in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25448156" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Fluoxetine is neuroprotective in slow-channel congenital myasthenic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23688972" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Quinine sulfate as a therapeutic option in a patient with slow channel congenital myasthenic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9546329" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Quinidine sulfate therapy for the slow-channel congenital myasthenic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5547870" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The clinical and biochemical effects of excess magnesium in the newborn.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4330762" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Antibiotic-induced neuromuscular blockade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16163636" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Botulism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7005856" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Infant botulism: clinical spectrum and epidemiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15917401" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Infant botulism in the age of botulism immune globulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18595978" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Global occurrence of infant botulism, 1976-2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16082001" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : First case of infant botulism caused by Clostridium baratii type F in California.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19906896" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : First report worldwide of an infant botulism case due to Clostridium botulinum type E.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25879901" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Notes from the field: infant botulism caused by Clostridium baratii type F - Iowa, 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15730893" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Recent advances in infant botulism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3887319" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Clinical, laboratory, and environmental features of infant botulism in Southeastern Pennsylvania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7030764" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Infant botulism: epidemiology and relation to sudden infant death syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24924163" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Molecular epidemiology of infant botulism in California and elsewhere, 1976-2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/399377" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Food and environmental aspects of infant botulism in California.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7038077" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Protective role of human milk against sudden death from infant botulism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11465845" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Infant botulism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16452558" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Human botulism immune globulin for the treatment of infant botulism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16140690" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Catastrophic presentation of infant botulism may obscure or delay diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2221848" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Relapse of infant botulism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37004956" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Duration of Fecal Excretion of Clostridium Botulinum and Botulinum Neurotoxin in Patients Recovering from Infant Botulism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8299297" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Infant botulism. A review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8299297" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Infant botulism. A review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21536632" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Clinical reasoning: an unexpected diagnosis in a 4-month-old infant with lethargy and H1N1 influenza.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6312310" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Clinical electrophysiology of infantile botulism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14021257" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Neuromuscular transmission in the newborn infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4801888" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Studies of neuromuscular function in the newborn. I. A comparison of myoneural function in the full term and the premature infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17403857" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Clinical mimics of infant botulism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24558013" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Medical treatment for botulism.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
